血清α-1-微型血球蛋白作为2型糖尿病患者多重并发症的预测因子
Li-Chao Ge1, Yu-Ling Zhang2,3, Gui-Liang Peng3
1Department of Endocrinology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing 210002, Jiangsu Province, China.
World journal of diabetes
|October 20, 2025
概括
血清α-1-微型血球蛋白 (α1-MG) 水平升高与糖尿病并发症的风险增加有关,包括2型糖尿病患者的脏病,视网膜病,神经病和左心室缩. 这表明α1-MG可以作为这些条件的有价值的预测生物标志物.
科学领域:
- 内分泌学 在内分泌学.
- 生物标志物发现发现
- 糖尿病学 糖尿病学
背景情况:
- 在2型糖尿病 (T2DM) 中血糖控制不佳往往导致严重的并发症,如糖尿病脏病 (DN),视网膜病变 (DR),外围神经病变 (DPN) 和左心室缩 (LVH).
- 对高风险T2DM患者的早期诊断和干预对于改善结果至关重要.
- 血清α-1-微型血球蛋白 (α1-MG) 正成为糖尿病相关疾病的潜在生物标志物.
研究的目的:
- 调查血清α1-MG水平与T2DM患者DN,DR,DPN和LVH的存在之间的关联.
- 评估血清α1-MG对这些糖尿病并发症的预测值.
主要方法:
- 一项涉及5045名T2DM患者的回顾性研究.
- 根据血清α1-MG水平,患者被分为四分之一.
- 多变量逻辑回归,受限立方线和可解释的机器学习模型被用于风险评估.
主要成果:
- 较高的血清α1-MG水平与DN,DR,DPN和LVH显著相关 (所有P<0.001).
- 每次α1-MG标准偏差的增加都与风险增加相关:DN为84%,DR为17%,DPN为14%,LVH为28%.
- 亚组分析和机器学习模型证实了α1-MG升高和这些T2DM并发症之间的联系.
结论:
- 在T2DM患者中,血清α1-MG的升高与DN,DR,DPN和LVH的风险增加独立相关.
- 血清α1-MG显示出作为主要糖尿病并发症预测生物标志物的潜力.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Nephrotic Syndrome I : Introduction
493
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
493
Nephrotic Syndrome II : Assessment and Medical Management
197
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
197
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Diabetes: Management and Pharmacotherapy
861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861


